Burden and Economic Impact of Vaccine-Preventable Cancer Mortality in Europe

Speaker(s)

Bencina G1, Oliver E2, Meiwald A2, Hughes R3, Sabale U4, Ovcinnikova O5, Morais E6, Ugrekhelidze D7, Weston G3
1MSD, Center for Observational and Real World Evidence (CORE), Madrid, Spain, 2Adelphi Values PROVE, Bollington, Cheshire, UK, 3Adelphi Values PROVE, Bollington, UK, 4MSD, Stockholm, Sweden, 5MSD UK, London, London, UK, 6MSD, Puteaux, France, 7MSD, Zurich, Switzerland

Presentation Documents

Objectives: The economic burden of cancer in Europe exceeds €100 billion annually. Human papillomavirus (HPV) and hepatitis B virus (HBV) are important causes of cancer that are potentially preventable with vaccination. This analysis estimates the burden of vaccine-preventable cancer by deaths and the indirect cost of years of life lost (YLL) across Europe.

Methods: The number of deaths and YLL across Europe in 2019 were sourced from the Institute for Health Metrics Evaluation (IHME) for the following indications: liver cancer caused by HBV (ICD-10 C22); head and neck cancers (C00-14 and C32); cancer of the cervix uteri (C53). The proportion of cancer mortality caused by HPV infection was calculated using attributable fractions. The monetary value of YLL was estimated by multiplying YLL by GDP per capita. Results were stratified by cancer type, country, and sex. Sensitivity and scenario analyses evaluated the robustness of results.

Results: In 2019, the modeled vaccine-preventable cancers in Europe caused 35,360 deaths, or 97 deaths per day, and 882,174 YLL, with an indirect cost due to premature mortality of €16,572,897,539. Approximately 64% of deaths and YLL were in females. Germany reported the highest number of deaths (13% of the European total) followed by France (11%) and Ukraine (10%). Overall, Eastern Europe reported the highest mortality (35% of total), while Western Europe incurred the greatest indirect cost (46% of total). Analysis showed that deaths occurred in younger age groups in Eastern European countries compared to the rest of Europe.

Conclusions: The results show a high burden of disease mortality and large economic impact of vaccine-preventable cancers caused by HPV and HBV in Europe. A long-lasting commitment to the allocation of adequate resources in preventive measures is therefore essential to decrease this burden.

Code

EE382

Topic

Economic Evaluation

Topic Subcategory

Work & Home Productivity - Indirect Costs

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology